Overview

The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age

Status:
Recruiting

Trial end date:
2024-06-17

Target enrollment:

Participant gender:

Summary

The purpose of this study is to examine the pharmacokinetics, safety, and tolerability of abacavir/dolutegravir/lamivudine dispersible and immediate release tablets in HIV-1-infected children less than 12 years of age.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators:

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
National Institute of Mental Health (NIMH)
ViiV Healthcare
ViiV Healthcare Ltd.

Treatments:

Abacavir
Dideoxynucleosides
Dolutegravir
Lamivudine
Triumeq